Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regeneratedfollicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
Minoxidil helps hair growth by increasing blood flow and prolonging the growth phase, but it doesn't address the root cause of hair loss, such as DHT sensitivity. Finasteride can help maintain some gains by blocking DHT, but stopping Minoxidil often leads to hair loss because the new hairs are dependent on it.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hairfollicles and sweat glands through heavy microneedling.
Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hairfollicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.